Logo

Foundation Medicine and Natera FoundationOne Tracker

Jun 09, 2021

Foundation Medicine and Natera have launch the research use version of FoundationOne Tracker, Foundation Medicine’s personalized circulating tumor DNA monitoring assay. FoundationOne Tracker combines Foundation Medicine's tissue-based comprehensive genomic profiling platform with Natera's expertise in ctDNA monitoring.

The assay uses optimized algorithms to identify tumor-specific variants and a personalized design to detect ctDNA in plasma, and is meant for use in both advanced- and early-stage research applications. Additionally, the fully integrated workflow between Foundation Medicine and Natera is expected to provide rapid inclusion of ctDNA monitoring results into retrospective research studies, the companies said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.